1. Home
  2. KRO vs DSGN Comparison

KRO vs DSGN Comparison

Compare KRO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kronos Worldwide Inc

KRO

Kronos Worldwide Inc

HOLD

Current Price

$8.18

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.27

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRO
DSGN
Founded
1916
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
853.8M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
KRO
DSGN
Price
$8.18
$12.27
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
2
4
Target Price
$6.00
$15.25
AVG Volume (30 Days)
325.7K
598.0K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
2.79%
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$1,859,400,000.00
N/A
Revenue This Year
$6.75
N/A
Revenue Next Year
$8.36
N/A
P/E Ratio
$90.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.08
$5.28
52 Week High
$9.17
$17.25

Technical Indicators

Market Signals
Indicator
KRO
DSGN
Relative Strength Index (RSI) 48.28 36.89
Support Level $5.97 $9.78
Resistance Level $9.03 $13.54
Average True Range (ATR) 0.39 0.65
MACD -0.13 -0.23
Stochastic Oscillator 11.11 3.56

Price Performance

Historical Comparison
KRO
DSGN

About KRO Kronos Worldwide Inc

Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The maximum of revenue comes from the United States.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: